JPMorgan raised the firm’s price target on Zai Lab (ZLAB) to $51 from $44 and keeps an Overweight rating on the shares. The firm updated models in the small-cap biotechnology space.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZLAB:
- Zai Lab announces acceptance of BLA for TIVDAK in cervical cancer
- Tesla upgraded, Coinbase initiated: Wall Street’s top analyst calls
- Zai Lab initiated with an Outperform at Scotiabank
- Zai Lab downgraded to Neutral from Buy at BofA
- Zai Lab’s Strong Financial Performance and Promising Pipeline Drive Buy Rating